New CEO for Artificial Intelligence drug discovery business Molplex‏

  • January 11, 2016

The highly innovative and world leading Artificial Intelligence drug discovery business Molplex, (based at BioCity, BioHub, Alderley Park), has appointed Victoria Camargo as its CEO to drive success in the company.

Victoria replaces co-founder of Molplex, Dr David Leahy, and steps up to CEO after three years as the company’s financial director, bringing with her invaluable experience and knowledge gained at blue-chip and high growth companies.

This appointment comes at a time of considerable activity for Molpex. The company has recently signed a significant commercial deal with Astra Zeneca to develop novel cancer treatments, and is currently engaged in a fund-raising round after securing further investment from the North West Fund for Biomedical (NWF4B) managed by Spark Impact.

Molplex designs novel therapeutics for various diseases using its pioneering Artificial Intelligence technology, allowing the development of more effective treatments faster and at a significantly lower cost.

The company is working in close partnerships with Pharmaceutical companies and academic researchers with an aim towards discovering novel therapeutics to treat cancer and various niche but valuable disease areas.

Victoria said: “I’m extremely proud to be able to lead Molplex at such an exciting time for the company. The investment from the NWF4B will help Molplex’ progress potential new drugs into efficacy trials and apply our AI technology to generate new personalised treatments for patients around the world.”

Ned Wakeman, director of BioHub said:

“Molplex is a very innovative business developing at an impressive rate. Our own growth is only possible with the growth of our tenants and partners and they are leading the way here at BioHub. It is a hugely exciting time for them and I wish them well.”

 

Company information
Press For Attention PR 6th floor City Gate East, Tollhouse Hill Nottingham NG1 5FS